{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:19:04Z","timestamp":1770985144927,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Xi'an Janssen Pharmaceutical Ltd. Beijing, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11011-017-9992-5","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T01:03:02Z","timestamp":1489539782000},"page":"891-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of escitalopram in treatment of severe depression in Chinese population"],"prefix":"10.1007","volume":"32","author":[{"given":"Tianmei","family":"Si","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiru","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maosheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jicheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Rui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Cuili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"9992_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1370\/afm.349","volume":"3","author":"B Arroll","year":"2005","unstructured":"Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:449\u2013456. doi: 10.1370\/afm.349","journal-title":"Ann Fam Med"},{"key":"9992_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.yic.0000194377.88330.1d","volume":"21","author":"DS Baldwin","year":"2006","unstructured":"Baldwin DS, Cooper JA, Huusom AK, Hindmarch I (2006) A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21:159\u2013169. doi: 10.1097\/01.yic.0000194377.88330.1d","journal-title":"Int Clin Psychopharmacol"},{"key":"9992_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1055\/s-2007-984398","volume":"40","author":"B Bandelow","year":"2007","unstructured":"Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40:152\u2013156. doi: 10.1055\/s-2007-984398","journal-title":"Pharmacopsychiatry"},{"key":"9992_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/11631890-000000000-00000","volume":"32","author":"A Bose","year":"2012","unstructured":"Bose A, Tsai J, Li D (2012) Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 32:373\u2013385. doi: 10.2165\/11631890-000000000-00000","journal-title":"Clin Drug Investig"},{"key":"9992_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1185\/030079906x115513","volume":"22","author":"JP Boulenger","year":"2006","unstructured":"Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M (2006) A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 22:1331\u20131341. doi: 10.1185\/030079906x115513","journal-title":"Curr Med Res Opin"},{"key":"9992_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4088\/JCP.v63n0410","volume":"63","author":"WJ Burke","year":"2002","unstructured":"Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331\u2013336","journal-title":"J Clin Psychiatry"},{"key":"9992_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4021\/jocmr2009.12.1275","volume":"1","author":"F Canan","year":"2009","unstructured":"Canan F, Ataoglu A (2009) Effect of escitalopram on white blood cells in patients with major depression. J Clin Med Res 1:290\u2013291. doi: 10.4021\/jocmr2009.12.1275","journal-title":"J Clin Med Res"},{"key":"9992_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/s0140-6736(09)60046-5","volume":"373","author":"A Cipriani","year":"2009","unstructured":"Cipriani A et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746\u2013758. doi: 10.1016\/s0140-6736(09)60046-5","journal-title":"Lancet"},{"key":"9992_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1023\/B:JOBA.0000045340.38371.04","volume":"26","author":"JC Cole","year":"2004","unstructured":"Cole JC et al (2004) Structural validation of the Hamilton depression rating scale. J Psychopathol Behav 26:241\u2013254","journal-title":"J Psychopathol Behav"},{"key":"9992_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/YIC.0b013e328303ac5f","volume":"23","author":"K Demyttenaere","year":"2008","unstructured":"Demyttenaere K, Andersen HF, Reines EH (2008) Impact of escitalopram treatment on quality of life enjoyment and satisfaction questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol 23:276\u2013286. doi: 10.1097\/YIC.0b013e328303ac5f","journal-title":"Int Clin Psychopharmacol"},{"key":"9992_CR11","doi-asserted-by":"publisher","unstructured":"Diagnostic and statistical manual of mental disorders (2000). 4th ed., text rev. American Psychiatric Association doi: 10.1176\/appi.books.9780890423349","DOI":"10.1176\/appi.books.9780890423349"},{"key":"9992_CR12","first-page":"1171","volume":"51","author":"B Gandek","year":"1998","unstructured":"Gandek B et al (1998) Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International Quality of Life Assessment J Clin Epidemiol 51:1171\u20131178","journal-title":"International Quality of Life Assessment J Clin Epidemiol"},{"key":"9992_CR13","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.4088\/JCP.14m09025","volume":"75","author":"ML Gerra","year":"2014","unstructured":"Gerra ML, Marchesi C, Amat JA, Blier P, Hellerstein DJ, Stewart JW (2014) Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant? J Clin Psychiatry 75:e939\u2013e944. doi: 10.4088\/JCP.14m09025","journal-title":"J Clin Psychiatry"},{"key":"9992_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0006-3223(02)01499-3","volume":"53","author":"L Grunhaus","year":"2003","unstructured":"Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN (2003) A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 53:324\u2013331","journal-title":"Biol Psychiatry"},{"issue":"1","key":"9992_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/2229-3485.173771","volume":"7","author":"BM Gupta","year":"2016","unstructured":"Gupta BM, Zargar SH, Arora M, Tandon VR (2016) Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: a preliminary 1-year prospective randomized open label comparative trial. Perspectives in Clinical Research 7(1):45\u201350. doi: 10.4103\/2229-3485.173771","journal-title":"Perspectives in Clinical Research"},{"issue":"6","key":"9992_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1017\/S146114571100112X","volume":"15","author":"S Kasper","year":"2012","unstructured":"Kasper S, Ebert B, Larsen K, Tonnoir B (2012) Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. Int J Neuropsychopharmacol 15(6):715\u2013725. doi: 10.1017\/S146114571100112X","journal-title":"Int J Neuropsychopharmacol"},{"key":"9992_CR17","first-page":"122","volume":"31","author":"SH Kennedy","year":"2006","unstructured":"Kennedy SH, Andersen HF, Lam RW (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122\u2013131","journal-title":"J Psychiatry Neurosci"},{"issue":"433","key":"9992_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1600-0447.2007.00966.x","volume":"115","author":"LV Kessing","year":"2007","unstructured":"Kessing LV (2007) Epidemiology of subtypes of depression. Acta Psychiatr Scand Suppl 115(433):85\u201389. doi: 10.1111\/j.1600-0447.2007.00966.x","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"9992_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593\u2013602. doi: 10.1001\/archpsyc.62.6.593","journal-title":"Arch Gen Psychiatry"},{"key":"9992_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40263-015-0267-6","volume":"29","author":"AL Khoo","year":"2015","unstructured":"Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP (2015) Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs 29:695. doi: 10.1007\/s40263-015-0267-6","journal-title":"CNS Drugs"},{"key":"9992_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/14656560902849258","volume":"10","author":"CD Kilts","year":"2009","unstructured":"Kilts CD, Wade AG, Andersen HF, Schlaepfer TE (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10:927\u2013936. doi: 10.1517\/14656560902849258","journal-title":"Expert Opin Pharmacother"},{"key":"9992_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/ppa.s22495","volume":"6","author":"E Kirino","year":"2012","unstructured":"Kirino E (2012) Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 6:853\u2013861. doi: 10.2147\/ppa.s22495","journal-title":"Patient Prefer Adherence"},{"key":"9992_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11136-014-0811-8","volume":"24","author":"S K\u00f6hler","year":"2015","unstructured":"K\u00f6hler S, Unger T, Hoffmann S, Mackert A, Ross B, Fydrich T (2015) The relationship of health-related quality of life and treatment outcome during inpatient treatment of depression. Qual Life Res 24:641\u2013649. doi: 10.1007\/s11136-014-0811-8","journal-title":"Qual Life Res"},{"issue":"6","key":"9992_CR24","doi-asserted-by":"publisher","first-page":"VC05","DOI":"10.7860\/JCDR\/2015\/12371.6092","volume":"9","author":"RB Komaram","year":"2015","unstructured":"Komaram RB, Nukala S, Palla J, Nambaru LR, Kasturi SM (2015) A comparative study of efficacy and safety of agomelatine and escitalopram in major depressive disorder. J Clin Diagn Res 9(6):VC05\u2013VC08. doi: 10.7860\/JCDR\/2015\/12371.6092","journal-title":"J Clin Diagn Res"},{"key":"9992_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/archpsyc.1989.01810100087016","volume":"46","author":"DJ Kupfer","year":"1989","unstructured":"Kupfer DJ, Frank E, Perel JM (1989) The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 46:771\u2013775","journal-title":"Arch Gen Psychiatry"},{"key":"9992_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4306\/pi.2010.7.4.231","volume":"7","author":"BH Lee","year":"2010","unstructured":"Lee BH, Kim YK (2010) The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 7:231\u2013235. doi: 10.4306\/pi.2010.7.4.231","journal-title":"Psychiatry Investig"},{"key":"9992_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/00005650-200007000-00008","volume":"38","author":"LA Lenert","year":"2000","unstructured":"Lenert LA, Sherbourne CD, Sugar C, Wells KB (2000) Estimation of utilities for the effects of depression from the SF-12. Med Care 38:763\u2013770","journal-title":"Med Care"},{"key":"9992_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.yic.0000074988.54339.7c","volume":"18","author":"UM Lepola","year":"2003","unstructured":"Lepola UM, Loft H, Reines EH (2003) Escitalopram (10-20 mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211\u2013217. doi: 10.1097\/01.yic.0000074988.54339.7c","journal-title":"Int Clin Psychopharmacol"},{"key":"9992_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/YIC.0b013e32836458e2","volume":"28","author":"HL Lin","year":"2013","unstructured":"Lin HL et al (2013) Comparison of escitalopram and paroxetine in the treatment of major depressive disorder. Int Clin Psychopharmacol 28:339\u2013345. doi: 10.1097\/YIC.0b013e32836458e2","journal-title":"Int Clin Psychopharmacol"},{"key":"9992_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mehy.2011.03.017","volume":"77","author":"JM Loftis","year":"2011","unstructured":"Loftis JM (2011) Sertoli cell therapy: a novel possible treatment strategy for treatment-resistant major depressive disorder. Med Hypotheses 77:35\u201342. doi: 10.1016\/j.mehy.2011.03.017","journal-title":"Med Hypotheses"},{"issue":"4","key":"9992_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4103\/0253-7613.135959","volume":"46","author":"N Maity","year":"2014","unstructured":"Maity N, Ghosal MK, Gupta A, Sil A, Chakraborty S, Chatterjee S (2014) Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol 46(4):433\u2013437","journal-title":"Indian J Pharmacol"},{"key":"9992_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/da.20222","volume":"25","author":"PX Mao","year":"2008","unstructured":"Mao PX et al (2008) Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety 25:46\u201354. doi: 10.1002\/da.20222","journal-title":"Depress Anxiety"},{"key":"9992_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442. doi: 10.1371\/journal.pmed.0030442","journal-title":"PLoS Med"},{"key":"9992_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/da.22063","volume":"30","author":"RS McIntyre","year":"2013","unstructured":"McIntyre RS et al (2013) Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 30:515\u2013527. doi: 10.1002\/da.22063","journal-title":"Depress Anxiety"},{"key":"9992_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/ceor.s39492","volume":"5","author":"C Mencacci","year":"2013","unstructured":"Mencacci C, Di Sciascio G, Katz P, Ripellino C (2013) Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy Clinicoecon. Outcomes Res 5:87\u201399. doi: 10.2147\/ceor.s39492","journal-title":"Outcomes Res"},{"key":"9992_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389","journal-title":"Br J Psychiatry"},{"key":"9992_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0025-7125(05)70333-3","volume":"85","author":"JD Moore","year":"2001","unstructured":"Moore JD, Bona JR (2001) Depression and dysthymia. Med Clin North Am 85:631\u2013644","journal-title":"Med Clin North Am"},{"key":"9992_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00004850-200505000-00002","volume":"20","author":"N Moore","year":"2005","unstructured":"Moore N, Verdoux H, Fantino B (2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20:131\u2013137","journal-title":"Int Clin Psychopharmacol"},{"key":"9992_CR39","volume-title":"The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 vol I","author":"CJL Murray","year":"1996","unstructured":"Murray CJL, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 vol I. World Health Organization and Harvard School of Public Health. Cambridge, MA, Geneva and Boston"},{"key":"9992_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1471-244x-12-198","volume":"12","author":"H Nan","year":"2012","unstructured":"Nan H, Lee PH, McDowell I, Ni MY, Stewart SM, Lam TH (2012) Depressive symptoms in people with chronic physical conditions: prevalence and risk factors in a Hong Kong community sample. BMC Psychiatry 12:198. doi: 10.1186\/1471-244x-12-198","journal-title":"BMC Psychiatry"},{"key":"9992_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/08039480600790358","volume":"60","author":"L Nyboe Jacobsen","year":"2006","unstructured":"Nyboe Jacobsen L, Smith Lassen I, Friis P, Videbech P, Wentzer Licht R (2006) Bodily symptoms in moderate and severe depression. Nord J Psychiatry 60:294\u2013298. doi: 10.1080\/08039480600790358","journal-title":"Nord J Psychiatry"},{"key":"9992_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.pnpbp.2011.11.010","volume":"36","author":"HY Park","year":"2012","unstructured":"Park HY, Lee BJ, Kim JH, Bae JN, Hahm BJ (2012) Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. Prog Neuro-Psychopharmacol Biol Psychiatry 36:318\u2013323. doi: 10.1016\/j.pnpbp.2011.11.010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"9992_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.biopsych.2004.10.029","volume":"57","author":"DO Rumi","year":"2005","unstructured":"Rumi DO et al (2005) Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry 57:162\u2013166. doi: 10.1016\/j.biopsych.2004.10.029","journal-title":"Biol Psychiatry"},{"key":"9992_CR44","doi-asserted-by":"crossref","unstructured":"Sajatovic M, Ramirez LF (2012) Hamilton anxiety scale (HAM-A). In: Rating scales in mental health. 3rd edn. The John Hopkins University Press, Baltimore, USA.","DOI":"10.56021\/9781421406664"},{"key":"9992_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/yic.0000000000000023","volume":"29","author":"C Sanchez","year":"2014","unstructured":"Sanchez C, Reines EH, Montgomery SA (2014) A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 29:185\u2013196. doi: 10.1097\/yic.0000000000000023","journal-title":"Int Clin Psychopharmacol"},{"key":"9992_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-4684-8956-9_13","volume-title":"Self-Esteem","author":"H Tennen","year":"1993","unstructured":"Tennen H, Affleck G (1993) The puzzles of self-esteem a clinical perspective. In: Self-Esteem. Springer, US, pp 241\u2013262"},{"issue":"Suppl. 1","key":"9992_CR47","first-page":"17","volume":"61","author":"ME Thase","year":"2000","unstructured":"Thase ME (2000) Treatment of severe depression. J Clin Psychiatry 61(Suppl. 1):17\u201325","journal-title":"J Clin Psychiatry"},{"key":"9992_CR48","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.euroneuro.2013.05.011","volume":"23","author":"ME Thase","year":"2013","unstructured":"Thase ME, Larsen KG, Reines E, Kennedy SH (2013) The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 23:1391\u20131400. doi: 10.1016\/j.euroneuro.2013.05.011","journal-title":"Eur Neuropsychopharmacol"},{"key":"9992_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jad.2016.03.048","volume":"199","author":"T Udristoiu","year":"2016","unstructured":"Udristoiu T, Dehelean P, Nuss P, Raba V, Picarel-Blanchot F, de Bodinat C (2016) Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25\u201350\u2005mg\/day) and escitalopram (10\u201320\u2005mg\/day) in outpatients with major depressive disorder. A 12-week randomised double-blind comparative study. J Affect Disord 199:6\u201312","journal-title":"J Affect Disord"},{"key":"9992_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","volume":"17","author":"A Wade","year":"2002","unstructured":"Wade A, Michael Lemming O, Bang Hedegaard K (2002) Escitalopram 10 mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95\u2013102","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-017-9992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-9992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-9992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:43:07Z","timestamp":1692722587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-017-9992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["9992"],"URL":"https:\/\/doi.org\/10.1007\/s11011-017-9992-5","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}